Presence of Tumour and Higher Levels of LAG3-positive T-cells in the Blood May Be Necessary to Derive Clinical Benefit with Nivolumab Plus Relatlimab Over Nivolumab in Melanoma By Ogkologos - November 11, 2025 175 0 Facebook Twitter Google+ Pinterest WhatsApp Primary results of RELATIVITY-098 and translational evidence from RELATIVITY-098 and RELATIVITY-047 studies Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR New study to investigate breast cancer in ethnic minority groups July 11, 2023 Adjuvant Immunotherapy Approved for Some Patients with Lung Cancer October 26, 2021 Sound Waves Can Target Lymph Nodes And Help Kill Breast Cancer... November 22, 2019 Discovery of Tumor Suppressor Suggests New Cancer Treatment Strategies May 14, 2021 Load more HOT NEWS Indicators of Outcome Are Identified for Nivolumab Treatment of Patients with... Different Microbiota–Host Relationships Relevant to Distinct Immune Checkpoint Blockade Regimens Adjuvant Abemaciclib Combined with Endocrine Therapy Improves IDFS in HR-Positive, HER2−Negative,... Child Cancer Patient And His Dad Have A Little Fun When...
